eligibility_summary
Eligibility: Adults 18–75 with resected PDAC per NCCN (no metastasis), R0/R1, ECOG 0–1, adequate organ/marrow function, expected survival ≥3 months, consented, contraception if fertile. Exclude prior neoadjuvant/RT/systemic PDAC therapy, serious comorbidities/infections, other active cancers, bleeding/clotting disorders, postop issues delaying adjuvant >12 weeks, drug allergy, malabsorption, HIV/syphilis/active HBV/HCV, or if deemed unsuitable.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial tests: 1) Nimotuzumab (h-R3), a humanized IgG1 monoclonal antibody against EGFR. Mechanism: binds EGFR, blocks ligand-induced activation to inhibit downstream signaling (RAS/RAF/MEK/ERK, PI3K/AKT) and may trigger antibody-dependent cellular cytotoxicity (ADCC). 2) GX regimen: gemcitabine + capecitabine. Gemcitabine is a deoxycytidine analog (antimetabolite) that inhibits ribonucleotide reductase and is incorporated into DNA, halting DNA synthesis. Capecitabine is an oral prodrug of 5-FU (antimetabolite) that inhibits thymidylate synthase and disrupts RNA/DNA. Targets: EGFR-expressing pancreatic cancer cells and proliferating tumor cells via nucleotide/DNA synthesis pathways.